ICU

SeaStar Medical Holding Corporation · NASDAQ

Sector Health Technology
Industry Medical Specialties
Website eastarmedical.com
Employees(FY) 9
ISIN US81256L2034

Performance

+8.99%

-2.83%

-58.47%

-50.0%

-81.39%

YTD

-82.04%

Profile

SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. SeaStar Medical Holding Corporation is headquartered in Denver, Colorado.

Advanced Technical Analysis

Technical Analysis of ICU 2024-12-20

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 16 indicating strong downward pressure, while the Oscillators Score of 56 suggests a neutral stance. Overall, the Technical Score of 36 reinforces the bearish outlook, signaling caution for potential investors.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ICU

Stock Rank

Recent News & Updates

2024-12-10 17:30
SeaStar Medical Projects Multibillion-Dollar Market Potential for its Selective Cytopheretic Device in Initial Target Indications(Globenewswire)
2024-12-03 19:30
SeaStar Medical to Hold Business Update Conference Call on December 11, 2024(Globenewswire)
2024-12-02 19:30
SeaStar Medical Activates Sentara Norfolk General Hospital and Provides Enrollment Update in Adult AKI Pivotal Trial(Globenewswire)
2024-11-25 19:00
SeaStar Medical to Present at Noble Capital Markets' NobleCon20 on December 4, 2024(Globenewswire)
2024-11-21 19:30
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Support SeaStar Medical's Proposals to Ratify the Issuance of Shares and to Reduce the Number of Authorized Shares(Globenewswire)
2024-11-14 19:30
SeaStar Medical Reaches Milestone of 100th QUELIMMUNE Commercial Device as Shipments Begin to its Third Hospital Customer(Globenewswire)
2024-11-13 04:05
SeaStar Medical Reports Third Quarter 2024 Financial Results and Provides a Business Update(Globenewswire)
2024-11-05 20:00
FDA Grants Breakthrough Device Designation for SeaStar Medical's Selective Cytopheretic Device for Adults Undergoing Chronic Dialysis(Globenewswire)
2024-10-31 20:30
Record Monthly Enrollment Achieved in SeaStar Medical's Pivotal Adult AKI Trial(Globenewswire)
2024-10-30 20:30
SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE(Globenewswire)
2024-10-24 23:32
Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical's QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024 - Update(Globenewswire)
2024-10-24 20:30
Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical's QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024(Globenewswire)
2024-10-22 20:30
SeaStar Medical Announces that Stanford Medicine is Cleared to Actively Enroll Subjects in the Adult Acute Kidney Injury Pivotal Trial(Globenewswire)
2024-10-21 20:30
SeaStar Medical to Distribute QUELIMMUNE Directly to Hospital Customers(Globenewswire)
2024-10-17 20:30
SeaStar Medical Announces that Enrollment in its Adult Acute Kidney Injury Pivotal Trial Has Exceeded the Halfway Point Toward an Interim Analysis(Globenewswire)
2024-10-14 20:30
SeaStar Medical to Showcase New Mechanistic Data Highlighting the Immunomodulatory Effect of the Selective Cytopheretic Device in Acute Kidney Injury at ASN Kidney Week(Globenewswire)
2024-10-08 20:30
SeaStar Medical to Present at the 2024 Maxim Healthcare Virtual Summit(Globenewswire)
2024-10-07 20:30
SeaStar Medical Expands NEUTRALIZE-AKI Pivotal Trial Adding Two Premier Military Medical Facilities(Globenewswire)
2024-09-24 20:30
SeaStar Medical Reports Enrollment Momentum in Its Pivotal Adult AKI Trial(Globenewswire)
2024-09-04 20:00
SeaStar Medical to Webcast Fireside Chat at the H.C. Wainwright Global Investment Conference(Globenewswire)
2024-09-03 20:30
SeaStar Medical Strengthens Financial Position with Elimination of All Long-Term Debt(Globenewswire)
2024-08-22 17:45
SeaStar Medical Holding Corporation Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 6, 2024 to Discuss Your Rights - ICU(Prnewswire)
2024-08-13 04:38
SeaStar Medical Reports Second Quarter 2024 Financial Results and Provides a Business Update(Globenewswire)
2024-08-08 00:38
SeaStar Medical Holding Corporation Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky Before September 6, 2024 to Discuss Your Rights ICU(Globenewswire)
2024-07-25 21:00
Nuwellis Announces First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical's QUELIMMUNE Therapy at Cincinnati Children's(Globenewswire)
2024-07-22 20:30
First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical's FDA-Approved QUELIMMUNE Therapeutic Device(Globenewswire)
2024-07-16 21:00
Nuwellis Marks First Commercial Sale of QUELIMMUNE Therapy to Cincinnati Children's(Globenewswire)
2024-07-15 20:30
CMS Grants Category B Coverage for Adults with Acute Kidney Injury Enrolled in SeaStar Medical's Selective Cytopheretic Device Pivotal Trial(Globenewswire)
2024-07-11 20:30
SeaStar Medical Ships First QUELIMMUNE Product Order to U.S. Distribution Partner(Globenewswire)
2024-07-11 04:05
SeaStar Medical Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules(Globenewswire)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.